Technology | Information Technology | June 20, 2019

DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software

Software provides dosimetry functionality for molecular imaging and molecular radiotherapy

DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software

June 20, 2019 — DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet Onco Dose software for its oncology and yttrium-90 (Y-90) microsphere SIRT 3-D dosimetry components.

Planet Onco Dose is a comprehensive software platform dedicated to medical diagnosis aid, therapy response assessment aid, contouring for radiotherapy and internal dosimetry computation, using molecular imaging modalities.

Planet Onco Dose is a modular software suite composed of two main elements:

  • Planet Onco: The oncology module with core system features, comprehensive reviewing of multimodal molecular image series (computed tomography, magnetic resonance imaging, positron emission tomography, single photon emission computed tomography), fusion and registration, automatic and semi-automatic contouring of regions of interest, tumor segmentation, quantification, tumoral activity monitoring and therapy response assessment; and
  • Planet Dose: The dosimetry module including 3-D personalized voxel-based internal dosimetry computation dedicated to molecular radiotherapy (MRT)

Planet Onco provides advanced tools to display, co-register (including deformable registration), compute standardized uptake value and import/export results (contours and quantification results) to/from treatment planning systems and picture archiving and communication system (PACS) devices for assessment, treatment planning and response of patients undergoing a course of oncology treatments.

DOSIsoft has transferred its external radiation therapy advanced software technology to nuclear medicine and molecular radiotherapy. CE marked since March 2016, Planet Onco Dose is the first fully integrated imaging and personalized 3-D dosimetry platform for radionuclide-based therapies, according to the company.

Planet Onco Dose is intended to assist the user in the diagnosis, quantification and verification of radiation doses received by tissues as a result of administering permanent Y90 microsphere implants, as well as in therapy response follow-up.

The software provides tools for post-treatment absorbed dose calculation and evaluation on PET and SPECT images. The following functions are available to allow dose calculations for patients after they have received a treatment using permanent Yttrium-90 microspheres:

  • Three-dimensional (3-D) liver-lung shunt assessment;
  • Voxel-based dosimetry based on 90Y-microspheres-PET (or SPECT Bremsstrahlung) series;
  • Dose computation models: Local Deposition Method and Voxel S Value Dose Kernel Convolution approach;
  • Analysis down to any liver sub region: healthy liver, lobes, tumors, toxicity regions;
  • Advanced and interactive dosimetry quantification (profile, dose-volume histograms, statistics, etc.);
  • Ability to scale to known activity; and
  • Compatible with PET images acquired with another radioisotope (correction of branching ratio and decay parameters).

For more information: www.dosisoft.com

Related Content

SIR-Spheres Y-90 resin

SIR-Spheres Y-90 resin microspheres are released into the hepatic artery.

News | Nuclear Imaging | February 14, 2020
February 14, 2020 —  ...
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
SIR President Laura Findeiss, M.D., FSIR

SIR President Laura Findeiss, M.D., FSIR

News | Interventional Radiology | February 09, 2020
February 9, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the...
DSA image obtained approximately 24 hours after 1 mg/h IA tPA infusion, 500 U/h heparin via peripheral IV, and daily oral aspirin (81 mg) shows improved perfusion of digital arteries, albeit with suboptimal vascular blush of distal second and third phalanges

DSA image obtained approximately 24 hours after 1 mg/h IA tPA infusion, 500 U/h heparin via peripheral IV, and daily oral aspirin (81 mg) shows improved perfusion of digital arteries, albeit with suboptimal vascular blush of distal second and third phalanges. Photo courtesy of ARRS

News | Interventional Radiology | February 07, 2020
February 7, 2020 — An ahead-of-print...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26 percent of patients undergoing pulmonary resection for non-small-cell lung cancer (NSCLC)

A Purdue discovery being developed by On Target Laboratories Inc., illuminates lung cancer cells on a patient during surgery. The “fluorescent markers” help medical professionals identify and remove cancer cells during surgery and is shown to improve outcomes. The technology is beginning Phase 3 clinical trials. (Photo provided by On Target)

News | Molecular Imaging | February 06, 2020
February 6, 2020 — ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.